NASDAQ · IBRX
ImmunityBio, Inc.
$8.74-$0.07 (-0.79%)
ImmunityBio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.69% below the high.
Loading market information…
NASDAQ · REPL · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Replimune Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.19% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Replimune Group, Inc.’s next earnings report is currently expected on Feb 2, 2027, with estimated earnings per share of -$0.64. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Replimune Group, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:24 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2026 | Aug 7, 2025 | -$0.95-14.46% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q4 2025 | May 22, 2025 | -$0.82-9.33% vs estimate | $1.47M |
|---|
| Q3 2025 | Feb 12, 2025 | -$0.79-12.86% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
15 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 4 contributors · Median target $24.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.74-$0.07 (-0.79%)
ImmunityBio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.69% below the high.
$9.56-$5.25 (-35.45%)
Iovance Biotherapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 37.8% below the high.
$27.12-$0.14 (-0.51%)
Nurix Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.93% below the high.
$17.83-$0.22 (-1.22%)
Janux Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.55% below the high.
$2.29-$0.07 (-2.97%)
CytomX Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.11% below the high.
$7.09-$0.04 (-0.56%)
Agenus Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.23% below the high.
$11.31+$0.38 (+3.43%)
Lyell Immunopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.88% below the high.
$2.04+$0.03 (+1.49%)
Compugen Ltd.’s quoted price sits in the lower half of its reported 52-week range, 37.04% below the high.
